When the Cellular Cleanup System Runs Out of Power: Mitochondria, Lysosomes, and the Stages of Resolution Failure

We often talk about mitochondria as the “powerhouses” of the cell. That metaphor is useful, but incomplete. Mitochondria do not simply make energy. They help decide whether a cell can repair, recycle, adapt, or eventually fall into chronic dysfunction.

A recent review by Marzetti and colleagues, “Mitochondrial quality in aging and neurodegeneration: The emerging role of mitochondria-derived vesicles,” adds an important layer to this story. The authors describe how mitochondria maintain their quality through a coordinated system that includes proteostasis, fusion and fission, mitophagy, biogenesis, and a newer player: mitochondria-derived vesicles, or MDVs. These vesicles can selectively bud off damaged mitochondrial material and send it toward lysosomes, peroxisomes, or other cellular destinations for processing. In this sense, MDVs act like an early mitochondrial triage system, helping the cell remove damaged components before the whole mitochondrion needs to be destroyed.

This may seem like a technical detail, but it points to a bigger biological principle:

The cell’s ability to recover depends not only on detecting damage, but on having enough energetic capacity to resolve it.

Mitochondrial quality control is not just cleanup

Mitochondrial quality control, or MQC, is often described as a set of cleanup pathways. Damaged proteins are repaired or degraded. Damaged mitochondria are removed by mitophagy. New mitochondria are produced through biogenesis.

But this review makes clear that MQC is more dynamic than a simple waste-disposal system. MDVs allow mitochondria to selectively export damaged proteins, lipids, mitochondrial DNA, and other components without sacrificing the whole organelle. This is especially important in neurons, where mitochondria must support synaptic activity, ion balance, calcium handling, and long-distance axonal transport. Neurons cannot afford careless mitochondrial loss. They need precision.

The diagram in the review places MDVs alongside proteostasis, fusion–fission dynamics, mitophagy, and biogenesis. That visual framing is important: MDVs are not an isolated curiosity. They may be one of the earliest ways cells respond to mitochondrial stress.

In practical terms, MDVs may represent the difference between:

“This mitochondrion has a damaged part; remove the part.”

and

“This mitochondrion is beyond repair; remove the whole organelle.”

That distinction matters deeply for aging.

The mitochondria–lysosome connection

The previous study we discussed, showing that mitochondria help lysosomes stay acidic, fits beautifully into this framework.

Lysosomes are the cell’s recycling centers. They need an acidic internal environment to break down damaged proteins, organelles, and vesicular cargo. If lysosomal acidity weakens, degradation slows. Waste accumulates. Autophagy becomes inefficient. Mitochondrial quality control loses its endpoint.

This creates a crucial link:

Mitochondria do not only produce the damage that needs to be cleared. They also help power the system that clears it.

So when mitochondrial energy throughput becomes constrained, the problem is doubled. The cell produces more mitochondrial stress, while also losing the ability to finish the cleanup.

This is where the throughput-limit model becomes useful.

Throughput limit: not just mitochondrial dysfunction

In the usual language, aging and chronic disease are often described as states of “mitochondrial dysfunction.” But that word can be too broad. It can hide the sequence.

A more precise framing is mitochondrial throughput limitation.

This means the mitochondria may still be present, still active, and still responding — but their capacity to process substrate, move electrons through the respiratory chain, maintain redox balance, and generate usable ATP is no longer sufficient for the total burden placed on the cell.

When substrate supply, stress signaling, inflammation, glucose/lipid load, or hormonal activation exceed mitochondrial processing capacity, the system becomes congested.

NADH pressure rises. Redox balance shifts. ROS signaling increases. Damaged mitochondrial proteins and lipids accumulate. The cell then needs more MQC.

But MQC itself requires energy.

Vesicle formation requires membrane remodeling. Trafficking requires cytoskeletal transport. Lysosomal degradation requires acidification. Mitophagy requires coordinated signaling, autophagosome formation, fusion with lysosomes, and recycling. None of this is free.

So the core problem becomes:

A throughput-limited mitochondrion creates more cleanup demand while reducing the energy available for cleanup.

That is the beginning of resolution failure.

Stage 1: Adaptive triage

In the early stage, mitochondrial stress is present, but the cell can still respond.

MDVs may increase as a selective quality-control mechanism. Damaged mitochondrial components are packaged and delivered to lysosomes or other compartments. Mitophagy may remove more severely damaged mitochondria. Biogenesis may replace what is lost. Fusion and fission help redistribute mitochondrial contents and isolate damaged regions.

This is still an adaptive state.

The cell is saying:“There is stress, but I can manage it.”

This stage may correspond to fatigue, reduced reserve, or early metabolic inflexibility before structural damage is obvious. The person may still function, but recovery takes longer. The system is no longer effortless.

Stage 2: Congestion and MQC overload

With persistent stress, the mitochondrial burden increases.

More oxidized proteins, damaged lipids, misfolded proteins, and mitochondrial DNA fragments need to be handled. MDVs become more important. Mitophagy demand rises. Lysosomes receive more cargo.

But if ETC throughput is constrained, the cell may not have enough energetic support to maintain efficient vesicle trafficking and lysosomal degradation.

This is where the review becomes especially relevant. In aging-related physical frailty and sarcopenia, the authors describe a pattern in which circulating extracellular vesicles are increased, but mitochondrial markers within those vesicles are reduced. In other words, there may be more vesicle release, but poorer mitochondrial cargo handling. The authors interpret this as a possible sign that vesicle quantity and mitochondrial quality-control function may diverge with aging.

This is a powerful idea.

Aging cells may not simply release “more mitochondrial waste.” They may release more vesicles while becoming worse at properly selecting, routing, and degrading mitochondrial cargo.

The cell is now saying:“I am still responding, but the cleanup system is becoming inefficient.”

Stage 3: Lysosomal resolution failure

If mitochondria help sustain lysosomal acidity, then impaired mitochondrial throughput can directly weaken lysosomal function.

At this stage, the cell may still recognize damaged mitochondrial components. It may still initiate MDV formation or mitophagy. But the downstream degradative machinery becomes less effective.

This creates a backlog.

MDVs may not reach the correct compartment. Lysosomes may not degrade cargo efficiently. Autophagic flux may slow. Damaged mitochondria may persist. Mitochondrial-derived material may be redirected into extracellular vesicles.

The problem is no longer only damage production. It is failed resolution.

The cell is now saying:“I can identify the problem, but I cannot clear it fast enough.”

This stage connects mitochondrial dysfunction with impaired macroautophagy, one of the major hallmarks of aging. It also links mitochondrial stress to altered intercellular communication, because poorly processed mitochondrial cargo may leave the cell and influence neighboring cells or immune pathways.

Stage 4: Extracellular spillover and inflammatory signaling

When intracellular mitochondrial cleanup fails, mitochondrial components can appear outside the cell in extracellular vesicles. The review discusses this possibility and notes that mitochondrial components may act as damage-associated molecular patterns, or DAMPs, capable of contributing to sterile inflammation.

This is biologically important because mitochondria evolved from bacteria-like ancestors. When mitochondrial DNA, cardiolipin, or oxidized mitochondrial components appear in the wrong place, the immune system may interpret them as danger signals.

In this stage, mitochondrial stress is no longer contained within the cell. It becomes a communication problem.

The cell is now saying:“The internal cleanup system is overwhelmed; mitochondrial danger signals are spilling outward.”

This may help explain why mitochondrial dysfunction, chronic inflammation, frailty, sarcopenia, Alzheimer’s disease, Parkinson’s disease, and other age-related conditions often cluster together. They may not be separate problems. They may be different expressions of unresolved mitochondrial stress.

Stage 5: Chronic maladaptation

Over time, unresolved mitochondrial and lysosomal stress can become self-reinforcing.

Mitochondrial throughput limitation increases damage. Damage increases MQC demand. MQC demand increases lysosomal workload. Lysosomal inefficiency causes cargo backlog. Cargo backlog promotes inflammatory signaling. Inflammation further increases metabolic demand and mitochondrial stress.

The loop becomes chronic.

At this point, interventions aimed only at “stimulating mitochondria” may be incomplete. Pushing more substrate, more stimulation, or more energy demand into a congested system may worsen the backlog if resolution pathways are not restored.

The goal is not simply to make mitochondria work harder.

The goal is to restore flow.

Why this matters for aging and neurodegeneration

The review discusses Alzheimer’s disease, Parkinson’s disease, frailty/sarcopenia, and other conditions through the lens of MDV biology. Across these conditions, mitochondrial quality control, vesicle signaling, lysosomal handling, and inflammation appear closely connected.

In Alzheimer’s disease, altered mitochondrial vesicles and extracellular vesicle cargo may reflect disrupted mitochondrial handling in the brain. In Parkinson’s disease, circulating vesicles show altered mitochondrial signatures and inflammatory markers. In frailty and sarcopenia, extracellular vesicle patterns suggest that mitochondrial cargo recycling may become less efficient with age.

This supports a broader interpretation:

Neurodegeneration and frailty may involve not only mitochondrial damage, but failure of mitochondrial resolution.

The neuron, muscle cell, or immune cell may not collapse immediately. Instead, it may spend years adapting, rerouting, compensating, and triaging. Disease may emerge when these adaptive systems can no longer complete the repair cycle.

The ERM perspective: recovery is conditional

From the Exposure-Related Malnutrition framework, this is a natural fit.

ERM proposes that chronic exposure burden, stress signaling, inflammation, nutrient mismatch, and metabolic strain can create a state where the body is not simply deficient in isolated nutrients, but functionally constrained in how it allocates and uses resources.

The MDV–lysosome–mitochondria connection adds a cellular mechanism to that idea.

Recovery requires more than input. It requires resolution capacity.

Nutrients, oxygen, exercise, sleep, hormones, and mitochondrial substrates only help if the system can process them and clear the byproducts of adaptation. If throughput is blocked and lysosomal degradation is weak, the cell may be flooded with signals to repair but lack the capacity to complete repair.

This is why rest, circadian repair, protein adequacy, micronutrient sufficiency, redox balance, movement, and reduction of unnecessary stress load all matter. They are not separate lifestyle tips. They support the biological conditions under which mitochondrial quality control can finish its work.

A better way to frame mitochondrial aging

Instead of saying:

“Aging is caused by mitochondrial dysfunction.”

A more precise statement may be:

Aging involves progressive failure of mitochondrial resolution: the loss of capacity to process energetic load, maintain lysosomal degradation, clear damaged mitochondrial cargo, and return the cell from stress adaptation back to repair.

MDVs help us see this transition more clearly.

They are not just tiny vesicles. They are signs of how the cell negotiates mitochondrial stress. When MDV handling works, damaged components are removed quietly. When it fails, mitochondrial material may accumulate, spill outward, and amplify inflammation.

In this view, healthspan depends on the ability to keep mitochondrial flow moving:

substrates in → electrons through → ATP produced → damage cleared → lysosomes acidified → repair completed → inflammation resolved.

When that sequence breaks, the cell does not simply become “dysfunctional.”

It becomes stuck.

And perhaps aging is, in part, what happens when too many cells remain stuck in unfinished recovery.

Reference

Marzetti, E., Di Lorenzo, R., Calvani, R., Coelho-Júnior, H. J., D’Argento, E., Pesce, V., Landi, F., Bucci, C., Guerra, F., & Picca, A. (2026). Mitochondrial quality in aging and neurodegeneration: The emerging role of mitochondria-derived vesicles. Mechanisms of Ageing and Development, 231, 112167. https://doi.org/10.1016/j.mad.2026.112167.